TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review. November 14, 2003
TCL Archive NCI Contracts: Advisors OK Renewal Of chemoprevention Contracts By DCPC September 6, 1996
TCL Archive Clearinghouse Opens With Predictable Controversy; Brown Urges ‘Open Minds’ November 12, 1976
